Co-Diagnostics
CODX
82 hedge funds and large institutions have $42.7M invested in Co-Diagnostics in 2022 Q1 according to their latest regulatory filings, with 17 funds opening new positions, 24 increasing their positions, 27 reducing their positions, and 11 closing their positions.
55% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 11
34% more call options, than puts
Call options by funds: $4.17M | Put options by funds: $3.12M
6% more funds holding
Funds holding: 77 → 82 (+5)
0.14% less ownership
Funds ownership: 0.82% → 0.68% (-0.14%)
11% less repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 27
33% less capital invested
Capital invested by funds: $63.7M → $42.7M (-$21M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$2.01M |
| 2 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$1.94M |
| 3 |
Jane Street
New York
|
+$537K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$530K |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
+$501K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Russell Investments Group
London,
United Kingdom
|
-$2.16M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$1.94M |
| 3 |
PPA
Parametric Portfolio Associates
Seattle,
Washington
|
-$1.5M |
| 4 |
Millennium Management
New York
|
-$1.27M |
| 5 |
Goldman Sachs
New York
|
-$763K |
CODX Hedge Fund Activity: Q1 2022 in Review
82 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in Co-Diagnostics (CODX) for Q1 2022, worth a combined $42.7M — down 33% from $63.7M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new CODX positions and 11 closed out — a net gain of 6 holders — while 24 added to existing stakes and 27 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $2.01M. The largest seller was Russell Investments Group, exiting entirely with an estimated $2.16M sold.
- 82 institutional investors held Co-Diagnostics (CODX) as of Q1 2022, up from 77 in Q4 2021.
- Funds reported $42.7M of Co-Diagnostics stock for Q1 2022, down 33% quarter-over-quarter.
- 17 funds opened new Co-Diagnostics positions in Q1 2022 and 11 closed out, a net change of +6 holders.
- The largest Co-Diagnostics buyer in Q1 2022 was Renaissance Technologies, an estimated $2.01M added.
- The largest Co-Diagnostics seller in Q1 2022 was Russell Investments Group, an estimated $2.16M sold.
Based on aggregated 13F filings for Q1 2022.